The goal is to reduce the frequency of semaglutide injections from 52 to 12 times per year.
Phase 1 trial to evaluate safety and pharmacokinetics; companies plan to pursue overseas joint development based on domestic clinical data.
Daewoong Pharmaceutical announced on the 19th that it has received approval for an Investigational New Drug (IND) application for a Phase 1 clinical trial of 'TION-L002,' a once-monthly injectable obesity treatment candidate being co-developed with TionLab Therapeutics.
TION-L002 is a long-acting injectable based on semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. The two companies aim to extend the dosing interval from once a week to once a month, reducing the annual injection frequency from 52 to 12. This initiative is designed to alleviate the treatment burden for obesity patients who require long-term therapy.
The Phase 1 trial will evaluate the safety and pharmacokinetic characteristics of TION-L002, such as changes in drug concentration in the body after administration. The companies plan to assess the feasibility of the long-acting formulation by comparing it with a control drug and seek overseas joint development partners based on the domestic clinical data.
The companies have combined their respective drug delivery technologies to achieve once-monthly administration. TionLab Therapeutics' 'Quject®Sphere' technology coats the surface of drug particles with a special composition to prevent the drug from being released all at once immediately after injection. Daewoong Pharmaceutical's 'CURE®' technology uses an inlet nozzle process to ensure uniform particle size, allowing the drug to be released at a constant rate over a long period.
Lim Deok-soo, CEO of TionLab Therapeutics, stated that the company aims to develop a long-acting obesity treatment that can provide efficacy comparable to existing therapies with just once-monthly administration.
Park Sung-soo, CEO of Daewoong Pharmaceutical, said, "We will accelerate development to expand our global partnerships based on data secured from domestic clinical trials and provide more convenient treatment options to patients worldwide."







